Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 13/20 | 0.72 |
| ▸ | CDK9 | P50750 | 9/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.72 |
| ▸ | CDK1 | P06493 | 9/20 | 0.72 |
| ▸ | CCNK | O75909 | 8/20 | 0.72 |
| ▸ | CDK12 | Q9NYV4 | 8/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.72 |
| ▸ | CDK7 | P50613 | 7/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.72 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.72 |
| ▸ | CCNH | P51946 | 5/20 | 0.72 |
| ▸ | CDK4 | P11802 | 4/20 | 0.72 |
| ▸ | CCND1 | P24385 | 4/20 | 0.72 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.66 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13030940 | 1.00 | DYRK1A (1.00) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL13030939 | 1.00 | DYRK1A (1.00) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL13030951 | 0.96 | DYRK1A (0.92) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL14964249 | 0.91 | DYRK1A (0.82) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL14964304 | 0.91 | DYRK1A (0.82) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL13030937 | 0.89 | DYRK1A (0.79) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL13030936 | 0.89 | DYRK1A (0.79) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL3508659 | 0.89 | DYRK1A (0.79) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL14977879 | 0.88 | DYRK1A (0.79) | DYRK1ACDK2CDK9CDK5CDK1 | |
| SCHEMBL14964243 | 0.88 | DYRK1A (0.79) | DYRK1ACDK2CDK9CDK5CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-8450342-B2 | Perharidines as CDK inhibitors | CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | DYRK1A 2983/4885CDK2 2103/4885CDK9 2031/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | DYRK1A 1742/4885CDK2 1489/4885CDK9 2993/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | DYRK1A 1742/4885CDK2 1489/4885CDK9 2993/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | DYRK1A 2960/4885CDK2 1540/4885CDK9 2873/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | DYRK1A 2844/4885CDK2 1981/4885CDK9 2660/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | DYRK1A 4008/4885CDK2 2992/4885CDK9 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.